Bio-Techne to acquire Advanced Cell Diagnostics

Research supplier Bio-Techne Corp. (NASDAQ:TECH) will acquire Advanced Cell Diagnostics Inc. (Hayward, Calif.) for $250 million in cash up front plus up to $75 million in milestones. Bio-Techne expects the deal to close around Aug. 1.

Advanced Cell Diagnostics markets RNAscope, an in situ hybridization-based assay technology designed to detect single molecules of nucleic acids in intact cells. Its investors include Morningside Venture, New Leaf Venture Partners, Summit Partners and Kenson Ventures. ...